Jamie T. Wisz
23 IP cases indexed. Covers patent matters.
Cases Presided Over
23 cases indexed | Page 1 of 1
Penumbra, Inc. v.RapidPulse, Inc.
The PTAB held that all 21 claims of RapidPulse’s ’253 aspiration thrombectomy patent are unpatentable, finding them obvious over Teigen, Grey and other prior art. Penumbra’s petition succeeded, leading to a sweeping invalidation.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB held that all 20 claims of Exact Sciences' 11,634,781 patent are obvious over prior art, rendering them unpatentable. Geneoscopy successfully proved the combination of existing fecal screening methods made the claims non‑inventive.
Formycon AG v.Regeneron Pharmaceuticals, Inc.
Formycon secured an institution of IPR against Regeneron's VEGF‑antagonist formulation patent (10,464,992), covering claims 1‑18, after the Board found a reasonable likelihood of success.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global and HydraFacial settled their inter partes review disputes before the PTAB instituted a trial. The Board granted joint motions to terminate and to keep the settlement agreement confidential, ending the proceedings.
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis' nasal benzodiazepine formulation patent are obvious over Gwozdz, Meezan ’962 and Cartt ’784, rendering the patent entirely unpatentable.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies and Johns Hopkins settled their dispute over U.S. Patent 11,938,201, leading the PTAB to grant a joint motion to terminate the post‑grant review.
smaXtec Inc. et al. v.ST Reproductive Technologies, LLC et al.
The PTAB found that the challenged claims of patent 9844206 were unpatentable over prior art combinations, primarily citing Trevarthen and Laitinen/Buchanan/Liao. The Board adopted the Patent Owner's claim construction for 'implanted in an animal,' meaning implanted within the animal.
Penumbra, Inc. v.RapidPulse, Inc.
The PTAB rejected Petitioner's obviousness arguments against the '402 patent claims (1-20) related to a thrombectomy/aspiration system. The Board adopted an intrinsic definition of 'predetermined cycle' as fixed timing, finding that prior art combining Mullins and Yang did not teach this limitation.
Geneoscopy, Inc. v.Exact Sciences Corporation
Geneoscopy, Inc. successfully petitioned the PTAB to institute an IPR against Exact Sciences Corporation's patent (11634781). The Board found a reasonable likelihood of prevailing on all grounds, specifically regarding obviousness under 35 U.S.C. § 103.
smaXtec Inc. et al. v.ST Reproductive Technologies, LLC et al.
The PTAB has instituted an IPR proceeding challenging the validity of claims in patent 9844206, focusing on obviousness (35 U.S.C. § 103). The Petitioner successfully demonstrated a reasonable likelihood of prevailing by presenting strong arguments regarding prior art combination and claim construction.
smaXtec Inc. et al. v.ST Reproductive Technologies, LLC et al.
The PTAB granted institution for the IPR challenge against a patent covering animal management systems using RFID technology. The Petitioner successfully argued that prior art references, including Trevarthen and Laitinen/Buchanan/Liao, provided sufficient motivation to combine elements of the challenged claims.
smaXtec Inc. et al. v.ST Reproductive Technologies, LLC
The PTAB instituted the IPR for smaXtec Inc. against ST Reproductive Technologies, LLC after finding sufficient evidence of unpatentability in several claims. The Board specifically found that Claim 5 was anticipated by Harvey and determined there was a reasonable likelihood of obviousness for Claim 7 over Harvey and Rettedal.
PreOmics GmbH et al. v.The Brigham and Women’s Hospital, Inc.
PreOmics GmbH et al. successfully petitioned for institution in the IPR against The Brigham and Women’s Hospital, Inc., challenging claims related to sensor arrays for protein corona analysis. The Board found a reasonable likelihood of unpatentability based on grounds of anticipation (102) and obviousness (103).
Samsung Bioepis Co., Ltd. v.Regeneron Pharmaceuticals, Inc.
Samsung Bioepis sought to invalidate numerous claims of Regeneron Pharmaceuticals' ophthalmic formulations using grounds of obviousness (103). The PTAB denied institution based on a holistic Fintiv analysis, citing significant overlap with ongoing district court and MDL proceedings.
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over prior art references Gwozdz, Meezan ’962, and Cartt ’784, rendering the patent entirely unpatentable.
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over a combination of prior‑art references, rendering the patent entirely unpatentable.
Eunsung Global Corp. v.HydraFacial LLC et al.
HydraFacial and Eunsung Global settled their IPR dispute before the Board could institute a trial. The joint motion to terminate was granted, and the settlement agreement was kept confidential.
Formycon AG v.Regeneron Pharmaceuticals, Inc.
The PTAB denied Formycon AG's IPR against Regeneron Pharmaceuticals, Inc., citing substantial overlap with parallel district court proceedings (MDL). The Board found that the interests of system efficiency were best served by denying institution.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies and Johns Hopkins University settled their dispute over U.S. Patent 12,115,233, leading the PTAB to terminate the post‑grant review before institution.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB instituted an IPR in a colorectal cancer screening case, finding a reasonable likelihood that Geneoscopy's challenged claims are unpatentable. The Board accepted the petitioner's argument that combinations of various prior art references teach every limitation of the claims with a reason for combination.
Intas Pharmaceuticals, Ltd. et al. v.Atossa Therapeutics, Inc.
Intas Pharmaceuticals successfully secured the institution of IPR against Atossa Therapeutics over a drug polymorph patent (11,261,151), challenging claims based on anticipation and obviousness using prior art Liu.
Penumbra, Inc. v.RapidPulse, Inc.
The PTAB held that all 18 claims of RapidPulse’s ’883 aspiration‑thrombectomy patent are unpatentable after finding them obvious over Teigen, Grey and other prior art.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. and HydraFacial LLC settled their inter partes review disputes, leading the PTAB to terminate both IPRs before institution. The settlement agreement is treated as confidential business information.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.